Q2 EPS Estimate for BioXcel Therapeutics Cut by Analyst

BioXcel Therapeutics, Inc. (NASDAQ:BTAIFree Report) – Stock analysts at HC Wainwright dropped their Q2 2025 earnings per share estimates for shares of BioXcel Therapeutics in a research note issued on Monday, June 23rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($2.30) per share for the quarter, down from their previous estimate of ($2.24). The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($24.39) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q3 2025 earnings at ($2.57) EPS, Q4 2025 earnings at ($1.68) EPS, FY2025 earnings at ($8.03) EPS and FY2026 earnings at ($2.17) EPS.

Several other equities analysts also recently weighed in on the stock. Rodman & Renshaw started coverage on shares of BioXcel Therapeutics in a research note on Wednesday, March 19th. They issued a “buy” rating and a $65.00 target price for the company. RODMAN&RENSHAW upgraded shares of BioXcel Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 19th. Finally, Wall Street Zen upgraded BioXcel Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, BioXcel Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $42.60.

View Our Latest Stock Analysis on BioXcel Therapeutics

BioXcel Therapeutics Price Performance

Shares of BTAI opened at $2.05 on Wednesday. The firm has a market capitalization of $12.42 million, a PE ratio of -0.15 and a beta of -0.12. The company’s 50-day moving average is $1.61 and its 200-day moving average is $3.13. BioXcel Therapeutics has a fifty-two week low of $1.17 and a fifty-two week high of $25.12.

BioXcel Therapeutics (NASDAQ:BTAIGet Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($1.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.72) by $1.22. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.35 million.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Murchinson Ltd. acquired a new position in BioXcel Therapeutics in the first quarter valued at about $276,000. Squarepoint Ops LLC grew its stake in BioXcel Therapeutics by 203.9% during the 4th quarter. Squarepoint Ops LLC now owns 72,046 shares of the company’s stock worth $27,000 after buying an additional 48,336 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of BioXcel Therapeutics by 81.4% in the fourth quarter. Northern Trust Corp now owns 73,910 shares of the company’s stock valued at $28,000 after buying an additional 33,161 shares during the period. Goldman Sachs Group Inc. purchased a new stake in shares of BioXcel Therapeutics during the first quarter valued at $50,000. Finally, Wells Fargo & Company MN lifted its stake in BioXcel Therapeutics by 7.5% in the 4th quarter. Wells Fargo & Company MN now owns 199,010 shares of the company’s stock worth $74,000 after acquiring an additional 13,952 shares in the last quarter. Hedge funds and other institutional investors own 30.68% of the company’s stock.

About BioXcel Therapeutics

(Get Free Report)

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.

Read More

Earnings History and Estimates for BioXcel Therapeutics (NASDAQ:BTAI)

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.